Mesa Laboratories (MLAB) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Mesa Laboratories

NasdaqGS•Technology•Scientific & Technical Instruments

$120.87-0.04(<0.01%)Pre-market

Market Cap

$683.76M

P/E

142.5x

P/S

2.7x

P/B

3.6x

Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides sterility assurance testing and laboratory services to the dental and pharmaceutical industries. The Biopharmaceutical Development segment develops, manufactures, sells, and services automated systems for protein analysis (immunoassays) and peptide synthesis solutions. Its Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for hereditary disease screenings, pharmacogenetics, oncology related applications, and toxicology research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; and PurePep Symphony and Chorus instruments for peptide synthesis. Its Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as renal care, gas flow, environmental and process monitoring, and torque testing in pharmaceutical, laboratory, medical device, manufacturing, industrial, and environmental applications. This segment's products include continuous monitoring systems, data loggers, and torque testing systems under the DialyGuard, DryCal, DataTrace, and ViewPoint brands. Mesa Laboratories, Inc. was incorporated in 1982 and is headquartered in Lakewood, Colorado.

How this company scores

GoodMetricSide Score: 74/100

Strongest: Cash & Earnings Quality (25/25); weakest: Profitability (15/25).

Profitability15/25

Growth17/25

Balance Sheet & Red Flags17/25

Cash & Earnings Quality25/25

Strengths

Rising free cash flowRising earningsLow leverageCash-backed earnings

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 142.5x5y range 70.3x – 982.1x

Currently below its 9-quarter median.

P/S · 2.7x5y range 1.4x – 11.1x

Currently near its 20-quarter median.

P/B · 3.6x5y range 1.4x – 4.6x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

Some Concerns

Earnings Quality

Watch

FCF/Net Income has dropped below 0.7x in 4 quarters — monitor for earnings quality deterioration.

Share Dilution

Watch

Shares outstanding rose 4.5% — mild dilution. Compare to earnings growth to assess the net per-share impact.

Price & Volume

Market Cap $683.76M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $249.72M
Q. Revenue: $60.14M
TTM EBITDA: $27.58M
TTM Op. Income: $22.48M
Q. Op. Income: $7.03M
TTM Net Income: $4.80M
Q. Net Income: $2.83M
EPS: $0.5
Shares Out.: $5.66M

$249.72M in TTM revenue grew 3.0% YoY, reaching $60.14M last quarter. TTM EBITDA of $27.58M and TTM operating income of $22.48M show growth is flowing through to the bottom line. TTM net income of $4.80M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 64.9%
EBITDA Margin: 13.8%
Op. Margin: 11.7%
Net Margin: 4.7%

Op. margin of 11.7% is up 6.5% YoY — cost efficiency is improving. Net margin at 4.7% and gross margin of 64.9% show how much of each revenue dollar survives to profit. Over the past year, operating margin is up 127% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 142.5x
P/S Ratio: 2.7x
P/B Ratio: 3.6x

At 142.5x P/E, the stock trades above typical market levels — the market expects above-average growth. P/S of 2.7x and P/B of 3.6x provide additional context. P/E sits above typical market levels while revenue growth is below 5%. Over the past year, P/E is up 0% — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $419.22M
Cash: $30.70M
Long-Term Debt: $66.09M
Book Value: $188.76M
D/E Ratio: 0.4
Debt/EBITDA: 8.0

With $419.22M in assets and $66.09M in long-term debt, D/E is 0.4and book value is $188.76M — a conservative capital structure with a cushion to weather downturns. Across the last 8 quarters, debt/equity has fallen for 6 consecutive quarters — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $14.74M
TTM Free Cash Flow: $52.87M
FCF Margin: 21.2%
FCF / Net Income: 11.0

TTM FCF of $52.87M on $14.74M in operating cash flow. The FCF / Net Income ratio of 11.0x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has risen for 4 consecutive quarters — an improving trend.